Skip to content
Company Analysis

Esperion Therapeutics, Inc. ESPR

A comprehensive view of key metrics, scores, and financial health for Esperion Therapeutics, Inc.

Overview of Esperion Therapeutics, Inc.

ESPR NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Esperion Therapeutics, Inc. (ESPR), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $3.18, about 6.0% undervalued vs fair value, +27.2% 1Y return, ranked 816/1145 in sector.
Metrics Rev Growth 21.3% ROE 6.6% Gross Margin 68.0% Div Yield 0.00%
USD 3.18
0.00%
(Delayed)
• Vol 90d: 90.9%
52-Week Range
Market Cap
$822.04M
Enterprise Value
$915.95M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 100%
Confidence: 96%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.esperion.com
HQ Ann Arbor, MI
Employees 304
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$3
$3
$4
Current: $3.18 +6% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$403.1M
21.3%%
Gross Profit
$273.9M
3.9%%
R&D Expense
$47.9M
3.5%%
Operating Income (EBIT)
$63.8M
749.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
-20.5%
Poor

Weak cash conversion - investigate working capital

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
2/2
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Esperion Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.75), demonstrating competitive advantages.
  • Cost Leadership Position Operating margin at 82.5th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • ROIC Below WACC or Peers ROIC at 12.2th percentile suggests inefficient capital deployment.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.24), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
55
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing ESPR's balance between Growth (43.1%), Profitability (28.2%), and Safety (28.7%). Growth 43% Safety 29% Profitability 28%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

81th percentile vs peers
81
Key Signals
Rev Growth YoY 21.3% 83p Revenue CAGR 3Y 74.8% 93p EPS Growth YoY 60.5% 57p TSR 68.2% 90p
Strengths
  • Growth performance in top 20% of peers (percentile: 81)
  • Rev Growth YoY in top 20% of peers (21.3%, 83th percentile)
  • Revenue CAGR 3Y in top 20% of peers (74.8%, 93th percentile)
  • TSR in top 20% of peers (68.2%, 90th percentile)
  • Debt/FCF Ratio in top 20% of peers (-19.05, 100th percentile)
Risks

No significant risks identified for this axis.

Profitability

53th percentile vs peers
53
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

54th percentile vs peers
54
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Esperion Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$3.37
- - -
+6.0% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000